read note feb buysid
jefferi top note feb includ list near-term catalyst note
follow updat data analysi fda breakthrough design approv
rate note coronaviru also highlight addit report
contain uniqu insights/differenti view think worth revisit
industri what biopharma near-term catalyst could feb
front row new wamd data continu look great feb
industri breakthrough design approv rate thought feb
industri chart week car-t sale thing feb
volatil corona know feb
feedback recent strength feb
industri histor rate cancer co list feb
patienc virtu everyon feb
launch app thought set-up expect feb
increment stuff client ask patent disput feb
risdiplam continu show clinic benefit broader type sma patient kol
call suggest potenti substanti switch spinraza risdiplam
although difficult predict risdiplam market entri could meaning impact
spinraza adequ reflect current expect view
manag increasingli confid success lead product odevixibat
pfic data track sept estimate still blind note
increas confid success given success enrol well-toler high-
dose odevixibat second indic odevixibat biliari atresia plan
start pivot trial data estimate
event bascom palmer angiogenesi meet discuss evolv wamd
retina landscap per kol high-dos eylea may provid increment add valu
ad sever week treatment durat link competitor threat beovu like
subsid given recent safeti notic asr vasculitit advers event
beovu inject link host expert call friday discuss
recent develop beovu safeti issu impact wamd space link
imab feb initi imab buy pt see strong china
opportun gglobal upsid oncolog autoimmun space view imab
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
differenti uniqu dual-strategi busi model featur matur de-
risk china portfolio earli innov global pipelin intern
china pipelin provid base case signific upsid global pipelin
view risk-reward skew upsid data two global asset
posit data could lift share
insid addit comment team
pleas see import disclosur inform page report
ncna key data catalyst combin data protid
fu potenti medic confer pivot start data
could offer inflect point view
tct poster session present updat long-term
follow-up cgvhd along two studi competitor jakafi result compar
favor safeti durabl respons jakafi consist associ
cytopenia infect ibrutinib usag limit post approv due safeti
concern link feb present interim analysi pivotal/rockstar
trial late breaker tct data line expect
summar key takeaway md anderson car-nk studi publish nejm
data show cord-blood deriv car-nk cell develop anti-donor ab
one year though patient differ deplet regimen could influenc fate
data shown one treat patient anti-donor ab
threshold graft failur set studi fresh cell use md
protocol suggest cryopreserv could hurdl takeda
chri howerton key report
assum coverag buy rate pt see high chanc
lead drug tenapanor approv hyperphosphatemia estim
adjust market opportun esrd pt w/ upsid pre-dialysi pt
ptab rule uphold patent primarili due unpredict pk multi-day
treatment want over-interpret read-through see
applic strategi could potenti favor decis unsurprisingli
court reject vnda challeng fda lt anim tox studi actual
see clear event believ co strategi move forward
program stock sale see sig upsid given multipl nt lt pipelin
opportun interview sybx ceo recent mainli focus
 process expertis partner collabor think improv
formul capabl drive pipelin asset across platform
pleas see import disclosur inform page report
top note past week
pleas see import disclosur inform page report
tickertitled biopharma near-term catalyst could move stock februari row new wamd data continu look great get better februari design approv rate thought februari week car-t sale thing watch februari corona know management discuss februari recent strength februari rate cancer co list prospectsfebruari virtu everyon still invest year februari app thought set-up expectationsfebruari stuff client ask patent disput coronaviru updatefebruari dinner discuss new wamd drug come take share marketfebruari discuss w/mgmt min summar sec februari overhang remov step stockfebruari oncolog deal possibl come februari tidbit exec council report releas interest comment pricingfebruari neuro go gene neurodegener initi buyfebruari accept w/ mileston azn thought competitor data overhang clear soon vascepa sale remain solidfebruari acid approv launch expect earli aprilfebruari fine guidanc bring question explain februari download minutesfebruari new data angiogenesi revis conf agendafebruari stock w/ lot pot upsid parkinson drug show somethingfebruari nash data look also pot datapoint akrofebruari parkinson genetx data soon found separ pot catalyst februari upsid potenti import event buyfebruari like tenaci tenapanor assum coverag buy ptfebruari launch expect high decent set-up put numbersfebruari parkinson genetx data could increment improv confidencefebruari pill approv toow follow bemp script trackerfebruari underway alreadi see interest fl pt come ahead approvalfebruari setup ahead upcom fda meet scenario treefebruari summari crazi week viru super tuesday stocksfebruari soft guidanc due price dynam higher opexjanuari approv potenti row partnership come februari discuss point greater odd increas success tyvasofebruari phase breast cancer data come light imvexxi bijuva pivot annovera pt competitor risdiplam data show potenti downsid spinraza sfebruari lot wood chop inbrija maintain holdfebruari ipr decis shed light win strategyfebruari spinraza sale line competitor risdiplam approv mayjanuari remain confid day lot go pipelin recentlyfebruari lose view ts path forward herefebruari bioavail data look continu de-riskedfebruari korlym patent decis broad pipelin progressfebruari discuss livoletid prader-willi syndrom pw februari adapt studi design save time money w/out increas riskfebruari management discuss data like sept progress expand opptyfebruari equiti research
javatar bluematrix com/sellside/disclosur action call
inform compani recommend
report pleas visit websit http //
michael yee certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
biren amin certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
eun yang ph certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
mauri raycroft ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
chri howerton phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr corcept inc
jefferi group llc make market secur adr
jefferi group llc make market secur adr i-mab
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr kadmon hold inc
jefferi group llc make market secur adr nucana plc
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr synlog inc
jefferi group llc make market secur adr inc
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
co within next three month
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
inc within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic inc
within past twelv month inc client jefferi llc invest bank servic
provid
pleas see import disclosur inform page report
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
inc one affili within past twelv month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic
within past twelv month client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
one affili within past twelv month
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
i-mab within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic i-mab
within past twelv month i-mab client jefferi llc invest bank servic provid
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
i-mab one affili within past twelv month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic kadmon hold inc
within past twelv month kadmon hold inc client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
kadmon hold inc one affili within past twelv month
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
nucana plc within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic nucana plc
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
nucana plc one affili
within past twelv month nucana plc client jefferi llc invest bank servic
inform compani recommend
report pleas visit websit http //
javatar bluematrix com/sellside/disclosur action call
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
pleas see import disclosur inform page report
